| Name | Crest View Nursing Home |
|---|---|
| Location | 612 View St, New Lisbon, Wisconsin |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 60 |
| Occupancy Rate | 74.33% |
| Medicare ID (CCN) | 525581 |
| Legal Business Name | Mile Bluff Medical Center Inc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1932124898 |
| Organization Name | MILE BLUFF MEDICAL CENTER INC |
| Doing Business As | CREST VIEW NURSING HOME |
| Address | 612 View St, New Lisbon, WI 53950 |
| Phone Number | 608-562-3667 |
News Archive
Research published in the November issue of Anesthesiology describes development of a new Risk Stratification Index (RSI) that allows important clinical outcomes such as length-of-stay and mortality for surgical patients to be accurately compared among hospitals using only publically available billing data. The new risk stratification system is more accurate than existing outcomes measurements such as the Charlson Comorbidity Index (CCI) and the investigators have made it freely available.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference.
A new study shows that the prognosis is good for people who have epilepsy surgery, even 30 years after the surgery. The study is published in the June 14 issue of Neurology, the scientific journal of the American Academy of Neurology.
The appointment of Dutch pharmaceutical company Crucell, recently acquired by Johnson & Johnson, to the board of the GAVI Alliance is "sparking concerns over conflicts of interest and demands for tougher competition to reduce prices," the Financial Times reports.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Research published in the November issue of Anesthesiology describes development of a new Risk Stratification Index (RSI) that allows important clinical outcomes such as length-of-stay and mortality for surgical patients to be accurately compared among hospitals using only publically available billing data. The new risk stratification system is more accurate than existing outcomes measurements such as the Charlson Comorbidity Index (CCI) and the investigators have made it freely available.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference.
A new study shows that the prognosis is good for people who have epilepsy surgery, even 30 years after the surgery. The study is published in the June 14 issue of Neurology, the scientific journal of the American Academy of Neurology.
The appointment of Dutch pharmaceutical company Crucell, recently acquired by Johnson & Johnson, to the board of the GAVI Alliance is "sparking concerns over conflicts of interest and demands for tougher competition to reduce prices," the Financial Times reports.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.5 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.98 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 64.29 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.3 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 7.91 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.61 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.47 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.38 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 38.59 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 30.91 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 2.1 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 50.19 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 89.02 | 82.93 |
News Archive
Research published in the November issue of Anesthesiology describes development of a new Risk Stratification Index (RSI) that allows important clinical outcomes such as length-of-stay and mortality for surgical patients to be accurately compared among hospitals using only publically available billing data. The new risk stratification system is more accurate than existing outcomes measurements such as the Charlson Comorbidity Index (CCI) and the investigators have made it freely available.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference.
A new study shows that the prognosis is good for people who have epilepsy surgery, even 30 years after the surgery. The study is published in the June 14 issue of Neurology, the scientific journal of the American Academy of Neurology.
The appointment of Dutch pharmaceutical company Crucell, recently acquired by Johnson & Johnson, to the board of the GAVI Alliance is "sparking concerns over conflicts of interest and demands for tougher competition to reduce prices," the Financial Times reports.
› Verified 4 days ago